Suppr超能文献

恶性胶质瘤的新型疗法:局部问题?

Novel therapies for malignant gliomas: a local affair?

作者信息

Rainov Nikolai G, Söling A, Heidecke V

机构信息

Department of Neurosurgery, Central Clinic Augsburg, Germany.

出版信息

Neurosurg Focus. 2006 Apr 15;20(4):E9.

Abstract

Advances in medical and surgical treatments in the last few decades have resulted in quantum leaps in the overall survival of patients with malignant disease outside the central nervous system, whereas survival of patients with malignant gliomas (World Health Organization Grades III and IV) has remained essentially unchanged. Resection and external-beam fractionated radiotherapy remain the pillars of therapy for malignant gliomas and have shown significant beneficial effects on outcome in many clinical studies. On the other hand, numerous human trials with adjuvant agents, most of them administered systemically and causing serious complications and side effects, have not succeeded in achieving a noteworthy additional extension of survival duration, or have done so only with a considerable deterioration in the quality of life of the treated patients. The concept of local invasiveness of gliomas is not new, but only in the last one to two decades has significant attention been focused on the cell biology and molecular genetics of gliomas. Improved understanding of the fundamental features of tumor cells has resulted in the introduction and increasing clinical use of local therapies in which practitioners opt for spatially defined delivery methods and tumor-selective agents specifically designed to be used in the environment of a brain invaded by glioma. In this review, the authors summarize the key findings in some of the most important clinical studies of locally administered treatments for malignant glioma. A few such therapies have emerged in the last decade, and have shown considerable antitumor activity and a favorable profile of local and systemic side effects. These include biodegradable polymers for interstitial chemotherapy, targeted toxins administered by convection-enhanced delivery, and intra- and peritumorally injected genetically modified viruses conferring glioma-selective toxicity. In addition, areas of possible improvement of these therapies and essential further developments are outlined.

摘要

在过去几十年中,医学和外科治疗的进展使中枢神经系统以外恶性疾病患者的总体生存率有了巨大飞跃,而恶性胶质瘤(世界卫生组织III级和IV级)患者的生存率基本保持不变。手术切除和外照射分次放疗仍然是恶性胶质瘤治疗的支柱,并且在许多临床研究中已显示出对治疗结果有显著的有益影响。另一方面,众多使用辅助药物的人体试验大多通过全身给药,会引起严重并发症和副作用,未能成功显著延长生存期,或者只是在治疗患者的生活质量大幅下降的情况下才做到这一点。胶质瘤局部侵袭性的概念并不新鲜,但直到最近一二十年,才开始高度关注胶质瘤的细胞生物学和分子遗传学。对肿瘤细胞基本特征的深入了解促使了局部治疗方法的引入及临床应用的增加,在这些局部治疗中,医生选择空间限定的给药方式以及专门设计用于胶质瘤侵袭脑环境中的肿瘤选择性药物。在这篇综述中,作者总结了一些关于恶性胶质瘤局部给药治疗的最重要临床研究中的关键发现。在过去十年中出现了几种这样的疗法,它们显示出相当大的抗肿瘤活性以及良好的局部和全身副作用情况。这些疗法包括用于间质化疗的可生物降解聚合物、通过对流增强递送给药的靶向毒素,以及瘤内和瘤周注射的具有胶质瘤选择性毒性的基因改造病毒。此外,还概述了这些疗法可能改进的方面以及必要的进一步发展方向。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验